CD4+ Count–Guided Interruption of Antiretroviral Treatment | Zendy

Wafaa ElSadr | Zendy; Jens Lundgren | Zendy; James D. Neaton | Zendy; Fred M. Gordin | Zendy; D Abrams | Zendy; Roberto C. Arduino | Zendy; Abdel Babiker | Zendy; William J. Burman | Zendy; Nathan Clumeck | Zendy; Calvin Cohen | Zendy; David V. Cohn | Zendy; David A. Cooper | Zendy; Janet Darbyshire | Zendy; Sean Emery | Zendy; Gerd Fätkenheuer | Zendy; Brian Gazzard | Zendy; Birgit Grund | Zendy; Jennifer Hoy | Zendy; Karin L. Klingman | Zendy; M Losso | Zendy; Norman Markowitz | Zendy; J Neuhaus | Zendy; Andrew N. Phillips | Zendy; Claire Rappoport | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CD4+ Count–Guided Interruption of Antiretroviral Treatment

Author(s) -

Wafaa ElSadr,

Jens Lundgren,

James D. Neaton,

Fred M. Gordin,

D Abrams,

Roberto C. Arduino,

Abdel Babiker,

William J. Burman,

Nathan Clumeck,

Calvin Cohen,

David V. Cohn,

David A. Cooper,

Janet Darbyshire,

Sean Emery,

Gerd Fätkenheuer,

Brian Gazzard,

Birgit Grund,

Jennifer Hoy,

Karin L. Klingman,

M Losso,

Norman Markowitz,

J Neuhaus,

Andrew N. Phillips,

Claire Rappoport

Publication year - 2006

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa062360

Subject(s) - medicine , viral load , adverse effect , antiretroviral therapy , hazard ratio , clinical endpoint , human immunodeficiency virus (hiv) , immunology , confidence interval , randomized controlled trial

Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research